Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19174733 | 1.00 | MAPT (0.34) | MAPTCTSVCTSLCTSSCTSK | |
| SCHEMBL19375705 | 0.89 | MAPT (0.33) | MAPTCTSVCTSLCTSSCTSK | |
| SCHEMBL19174735 | 0.85 | CTSK (0.36) | MAPTCTSVCTSLCTSSCTSK | |
| SCHEMBL18469462 | 0.84 | MAPT (0.30) | MAPT | |
| SCHEMBL30530221 | 0.83 | MAPT (0.34) | MAPTCTSVCTSLCTSSCTSK | |
| SCHEMBL16869844 | 0.80 | CNR1 (0.32) | — | |
| SCHEMBL16819024 | 0.78 | CNR2 (0.31) | — | |
| SCHEMBL16819025 | 0.78 | CNR2 (0.31) | — | |
| SCHEMBL19174759 | 0.70 | ALDH1A1 (0.33) | BCHEALDH1A1 | |
| SCHEMBL1260916 | 0.69 | CNR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562058-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | HAVCR2, IFNAR1, ZC3HAV1 | MAPT 2270/4885CTSV 99/4885CTSL 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.